1 / 4

Arbitrary Unit

1.2. 1.2. 1.2. 1.2. 1.2. 1.2. 1.0. 1.0. 1.0. 1.0. 1.0. 1.0. 0.8. 0.8. 0.8. 0.8. 0.8. 0.8. 0.6. 0.6. 0.6. 0.6. 0.6. 0.6. 0.4. 0.4. 0.4. 0.4. 0.4. 0.4. 0.2. 0.2. 0.2. 0.2. 0.2. 0.2. 0. 0. 0. 0. 0. 0. Supplemental Figure 1. Specific siRNA treatments suppress

cooper-jarvis
Download Presentation

Arbitrary Unit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1.2 1.2 1.2 1.2 1.2 1.2 1.0 1.0 1.0 1.0 1.0 1.0 0.8 0.8 0.8 0.8 0.8 0.8 0.6 0.6 0.6 0.6 0.6 0.6 0.4 0.4 0.4 0.4 0.4 0.4 0.2 0.2 0.2 0.2 0.2 0.2 0 0 0 0 0 0 Supplemental Figure 1. Specific siRNA treatments suppress the mRNA expression of each PLC isoform in MIN-6 cells Non-targeting (NT) siRNA (open bars; n=5) or siRNA specific for each PLC isoform (closed bar; n=5) was applied to MIN-6 cells. After a 48 hr incubation, cells were subjected to RT-PCR analysis. PLC expression levels in MIN-6 cells were quantified and normalized relative to β-actin mRNA levels. *P <0.05, **P <0.01 versus NT siRNA-transfected MIN-6 cells assessed by unpaired t test. Data are presented as means ± SEM. PLCβ1 PLCβ2 PLCβ3 ** ** ** Arbitrary Unit Arbitrary Unit Arbitrary Unit NT PLCβ1 siRNA siRNA NT PLCβ2 siRNA NT PLCβ3 PLCγ1 PLCγ2 PLCδ1 ** * * Arbitrary Unit Arbitrary Unit Arbitrary Unit PLCγ1 PLCγ2 PLCδ1 siRNA NT siRNA NT siRNA NT

  2. siRNA NT PLC-β1 NT PLC-γ1 siRNA Supplemental Figure 2. Specific siRNA treatments suppress the protein levels of PLC-β1 and PLC-γ1 isoforms in MIN-6 cells Non-targeting (NT) siRNA or siRNA specific for each PLC-β1 and PLC-γ1 isoforms were applied to MIN-6 cells. After a 48 hr incubation, immunoblot analysis was performed with MIN-6 cells lysate, using a monoclonal anti- PLCβ1 antibody (sc-5291, Santa Cruz) or a polyclonal anti- PLCγ1 antibody (#2822, Cell Signaling).

  3. forward (5’ to 3’) reverse (5’ to 3’) β-actin TTGTAACCAACTGGGACGATATGG GATCTTGATCTTCATGGTGCTAGG CCATTCTCGGCCTTGACT GAPDH TGAAGGTCGGTGTGAACG PEPCK TTGCCTCCATGAAGTTTGAT GGCATTTGGATTTGTCTTCACT G6Pase AAAGAGACTGTGGGCATCAAATC AATGCCTGACAAGACTCCAGCC IL-6R CCAACCTTGTGGTATCAGCC TGGATGACGCATTGGTACTG PLC-β1 AAGCCAGATGGAAGAGGAGA GCGGATCTCATTGTGTTTCT PLC-β2 TCCTTCGAGTTCTCTGCACA TCTGGGGCATGTAGTTGGAA PLC-β3 TCCTTTGAGAACCATGTCG ATTCTTCACCAGGATACGGC PLC-γ1 GACTTCTCGGGACTTTGACC GTTAAGCCCTTGATCCACAT PLC-γ2 CGGAGGACAGTACAGATGAT TAGAGGATGGTGAAGCAACA PLC-δ1 GATTCACTCCTGCTTGCGA TCAATCTCCTCATCCTCCAG Supplemental Table 1. The oligonucleotide primers used for RT-PCR.

  4. 4A 5A 4B 4F 5B5C 5D 6A 6B Supplemental Table 2. Effects of several pretreatments on insulin content of MIN-6 cells and isolated islets Insulin contents of MIN-6 cells (1-5×106 cells/well) and isolated islets (10 islets/well) used in the experiments are indicated. Left column shows the Figure numbers corresponding to each pretreatments. Data are presented as means ± SEM. Insulin content (ng) Fig. Pretreatments

More Related